

Supplier Sustainability Guide

Guidance on AstraZeneca's minimum
supplier requirements

and

best practice for leadership in sustainability

April 2026





To support innovation,
we need to **transform** how
healthcare is delivered...



For the **health** of people,
society and the planet.



It's the
right thing to do.



This is **not** philanthropy,
or corporate social
responsibility.



This is **business critical**
and the **responsibility**
of all of us.



Welcome to AstraZeneca's Supplier Sustainability Guide

As companies in our supply chain, you are a vital part of AstraZeneca's transition to a more sustainable business, with increasingly resilient supply chains, ensuring the uninterrupted delivery of vital medicines to patients across the world.

This guide provides our minimum requirements to support these goals, confirms what good looks like, provides practical support, and helps you prioritise the most relevant steps for your business. It is not exhaustive and you should design your own program to deliver our sustainability requirements.

How to use this guide:

- **Section 1: Overview** — **Requirements** (non-negotiable, in contract or tied to legislation), **Expectations** (highly encouraged for best practice or as levers to deliver requirements), **Supporting programs** (sector initiatives and networks), and the **Business case** including AstraZeneca alignment with industry expectations, and where **decarbonisation programs fit on the journey to net zero**.
- **Section 2: Step-by-step for minimum requirements**, with **SME support** covering **SBTi**, **EcoVadis**, **CDP**, **Decarbonisation Plans for AstraZeneca-allocated emissions**, **Labour and Human Rights; Inclusion and Diversity (I&D)** and **Sustainable Sourcing**.
- **Section 3: Beyond Minimum Requirements** — Guidance to demonstrate sustainability leadership in **Human Rights**, **Renewable Electricity & Clean Heat**, **Product/Site Carbon Footprints**, **Biomaterials sourcing**, **Nature**, and **Sustainable Procurement**.
- **Section 4: Further Resources & Support** — Recommended external sources and how to contact us or access additional assistance.



Our sustainability strategy

Start with Section 1; complete Section 2; then use Sections 3–4 to deepen impact and access support.






Section 1: Overview

The foundation for working with AstraZeneca is our Code of Conduct for Third Parties

This document summarises what AstraZeneca believes is required to do the right thing and our Code of Conduct that all third parties who work with us, for us, or on our behalf should follow. In addition to the basic requirements to follow the law and act with integrity, **our Code of Conduct is part of our fundamental commitment to work only with others who embrace ethical standards consistent with ours.**

<https://www.astrazeneca.com/content/dam/az/PDF/Sustainability/Code-of-conduct-for-third-parties.pdf>



Contents

We do the right thing	4	Fair treatment	14
Working together	5	Wages, benefits and working hours	15
		Freedom of association	15
Ethics	6	Health and safety	16
Anti-bribery and anti-corruption	6	Worker protection	16
Anti-fraud	6	Process safety	16
Anti-tax evasion	7	Emergency preparedness and response	16
Trade controls and fair competition	7		
Product security	7	Environment	17
Animal research and welfare	8	Environmental authorisations and reporting	17
Conflicts of interest	8	Climate action	17
Patient safety and access to information	8	Waste and emissions to air, land and water	18
Data privacy	9	Resource use	18
Ethical and responsible data and AI	9		
Cyber security	10	Management systems and reporting	19
Confidentiality	10	Commitment and accountability	19
Product communication	10	Legal requirements	19
Sustainable sourcing and traceability	11	Managing your third parties	19
		Risk identification and management	19
Human and labour rights	12	Sustainability	20
Freely chosen employment, anti-slavery and anti-trafficking	12	Materiality assessment	20
Spotting the signs of modern slavery and forced labour	13	Standard setting	20
Child labour and young workers	13	Transparency in reporting	20
Inclusion and diversity	14	Communication, training and competency	20
Supplier inclusion and diversity	14	Continuous improvement	21
Non-discrimination	14	Identification and reporting of concerns	21



Supplier sustainability contractual and legal requirements

All suppliers are required to comply with our [Code of Conduct for Third Parties](#) which includes specific reference to **Human Rights** amongst other topics.

Refer to contract for a definitive list of requirements.

SBTi status – Near-Term Targets submitted for SBTi validation

SBTi commitment on SBTi portal and targets submitted for validation within 12 months of commitment.

Why: an SBTi target is a science-aligned, public indicator of a supplier's future decarbonisation.

AstraZeneca allocated emissions decarbonisation plan - 50% GHG emissions reduction

Agree a plan to reduce by 50% the carbon emissions relating to AstraZeneca's purchases.

Why: 98% of AstraZeneca's emissions are Scope 3. To achieve Net Zero by 2045, our suppliers must decarbonise the products and services we buy from them.

EcoVadis overall score - active scorecard with overall score >45

Complete an annual EcoVadis assessment and aim to improve your score year on year based on the corrective actions provided.

Why: EcoVadis helps us understand the sustainability maturity of a supplier across Environment, Ethics, Labour & Human Rights and Sustainable Procurement.

Inclusive policies & practices – shared via EcoVadis

Develop and maintain policies on inclusion and diversity within your organisation and supply chain, consistent with applicable laws, and report on progress via EcoVadis.

Why: to support inclusive business practices and compliance with applicable legal and contractual requirements.

Emissions data - scope 1&2, PLUS scope 3 cats 1-8

Provide your emissions data through the EcoVadis metrics section and update annually. Each year we also invite a number of suppliers to disclose through CDP free of charge.

Why: Supplier provided emissions data improves the quality of our Scope 3 reporting.

Specific suppliers only:

EUDR compliance

Suppliers delivering oil palm, cattle, cocoa, coffee, rubber, soy, wood, or related derived products to any of our EU sites must demonstrate that their goods are deforestation-free, legally produced, and traceable via geolocation coordinates.

Why: EU legislative requirement.

US Government Subcontract Flowdowns

Suppliers supporting AZ U.S. Government contracts must accept applicable U.S. Government flowdowns and terms & conditions.

Why: US Government Federal Acquisition Regulations requirement.

Sustainable sourcing – supply of natural raw materials must meet specific sustainable sourcing requirements, including third-party certification

Specific certifications to be communicated in 2026, guidance to follow.

Why: to ensure raw materials are reducing impact on nature and ensuring business resilience

Contractual requirements apply to suppliers above \$250k annual spend with only select suppliers above \$1.3m annual spend invited to CDP.

Certain organisation types including governments, HCOs, Academic institutions, single person companies and co-operative organisations are exempt from some requirements. For questions on eligibility contact sustainable.procurement@astrazeneca.com



Supplier Expectations to meet AstraZeneca requirements

Supports meeting our contractual/legal requirements and sustains an ongoing business relationship

EcoVadis Carbon Management Level – Advanced*

Work on improving the carbon management level annually and address all actions identified to improve the scorecard, including provision of all carbon metrics.

Why: To help us understand the carbon maturity, in turn allowing tailored engagement and support.

Achieve EcoVadis Labor & Human Rights sub-score above 45

Respecting & advancing Human Rights, & promoting Decent Work Conditions in our supply chain.

Why: To demonstrate upholding labor and human rights risks in our supply chain.

Renewable Electricity (RE) - Achieve 80% RE and target 100% RE by 2030

Achieve 80% RE at global corporate level, and 100% RE at sites manufacturing for AZ by 2030. Suppliers to use Energize and/or SMI PPA programs or drive own program.

Why: A key lever for all businesses to deliver decarbonisation

Clean Heat - Achieve 20% at global level AND target 100% clean heat by 2030

Achieve 20% Clean Heat at global corporate level, and 100% at sites manufacturing for AZ by 2030. Suppliers to use AZ Clean Heat and/or SMI Clean Heat or drive own program.

Why: A key lever for many businesses to deliver decarbonisation

Adherence to AstraZeneca's biomaterials principles for proposed switches of any fossil derived fuel, solvent or plastic to a naturally derived feedstock

Why: To avoid unintended consequences on nature by decarbonization-driven biomaterial switches.

Worldfavor - Profile active AND all allocated questionnaires answered

Maintain an active profile on this disclosure platform to provide specific sustainability evidence when requested. (evidence not collected on other platforms)

Why: To provide data which guide our sustainability and supplier engagement planning



Programs available to support suppliers

Click titles to access the programs external page



Lead in Sustainability Accelerator for Small Businesses

Four- month annual intensive program to enable small businesses to build sustainability foundations, assess their impacts, navigate through EcoVadis, SBTi and CDP and develop roadmap and action plan aligned to AstraZeneca expectations .

Sustainable Markets Initiative

Sustainable Markets Initiative

A CEO-led coalition mobilizing private-sector action for sustainability, including programs to catalyze green electricity and low-carbon heat adoption in industry. By promoting green electricity power purchase agreements and green heat solutions, it supports suppliers in transitioning away from fossil heat and power to meet net-zero pathways.



Activate by Secaro (previously Manufacture 2030) [for Manufacturing suppliers]

A supplier-focused platform that assesses facility-level sustainability performance and provides targeted action plans to reduce carbon, waste, and resource use. AstraZeneca also uses Activate to collect data from suppliers' manufacturing sites for our products Life Cycle Assessments (LCAs).



Responsible Health Initiative (RHI)

An industry coalition powered by EcoVadis, where leading pharmaceutical and healthcare companies collaborate to improve sustainability, ethics, and environmental impact across global supply chains. It uses shared assessments to drive sustainability performance, mitigate risk, and enhance efficiency in the industry.



Converge by My Green Lab [for R&D and Manufacturing supplier labs]

A program and toolkit that standardizes and improves sustainability practices in laboratories through the My Green Lab Certification framework.

By guiding lab-based suppliers to adopt best practices (energy, water, waste, green purchasing), it measurably lowers environmental impact and supports alignment with pharmaceutical sector sustainability expectations.



Pharmaceutical Supply Chain Initiative

A pharmaceutical sector initiative that sets common principles and provides tools for responsible supply chain practices covering ethics, labor, health & safety and environment. By providing an industry standard for audits, and capability-building resources (also available to non-members) it helps improve performance, reduce risks, and meet AstraZeneca sustainability criteria.



Energize [renewable electricity program for all suppliers plus Tier-2 suppliers]

A cross-company initiative that enables pharmaceutical and healthcare suppliers to access renewable electricity through education, aggregated procurement, and market facilitation. By simplifying renewable electricity purchasing and aggregating demand, it reduces barriers to sourcing clean electricity and lowers/eliminates Scope 2 emissions.



Sustainable Procurement Pledge

A global movement of procurement professionals committed to integrating sustainability into purchasing decisions and supplier engagement. It supports the capability development of employees and incentivizes companies to improve environmental and social performance to win and retain business.



Secaro: The Clean Heat Program

The Clean Heat Program is a joint initiative from Secaro and ERM, with AstraZeneca as founding sponsor. It identifies practical, site-specific opportunities for heat generation, distribution, and end-use efficiency, and to transition where appropriate to lower carbon heat solutions. The assessment results in a tailored business case and action plan with prioritized measures, estimated emissions reductions, and implementation pathways.



How AstraZeneca's requirements can help your business

AstraZeneca – supplier relationship

AstraZeneca is committed to working with sustainable suppliers.

We will increasingly place our business with suppliers that meet our sustainability requirements.

(along with other service, commercial, quality and contract requirements)

1

Preparation for legislation

Sustainability regulation is evolving and increasing in all markets.

We will evolve our supply chain structures and due diligence to ensure we can continue to supply our medicines to patients globally.

2

Meet industry expectations

Our supplier expectations are similar to many other Pharmaceutical companies and are often developed in pre-competitive collaboration through industry networks such as PSCI and SMI

3

Talent attraction and retention

Employees and candidates are increasingly seeking jobs with environmentally and socially responsible organisations.

Establishing a public sustainability program to meet AstraZeneca requirements can support your recruitment.

4

Risk reduction

Supply chain risks pose a threat to business continuity as well as a company's reputation.

Investors recognise the value created or protected by operating comprehensive environmental and social governance.

Investors also consider 'revenue at risk' where companies are not aligned with customer requirements.

5



Sustainability embedded into our Procurement Process

Eligibility for 'Preferred Supplier' status

A SBTi commitment (at minimum) is a mandatory requirement* to obtain AstraZeneca's Preferred Supplier status.

Preferred Suppliers are prioritised in sourcing events.

10% minimum weighting for sustainability in RFX

With a 10% minimum sustainability weighting in our RFX sourcing, strong sustainability performance or provision of sustainable goods/services will directly boost your evaluation score and increase your likelihood of winning and retaining business with AstraZeneca.

Supplier Spotlight

Suppliers that support AstraZeneca goals by introducing sustainability innovation or demonstrating leadership may be featured in our monthly Supplier Sustainability Newsletters, available publicly on the AstraZeneca website.



Meeting industry expectations: SMI Supplier Targets

Sustainable Markets Initiative



OPEN LETTER TO SUPPLIER PARTNERS ON CLIMATE AND NATURE ACTION FROM MEMBERS OF THE SUSTAINABLE MARKETS INITIATIVE (SMI) HEALTH SYSTEMS TASK FORCE

21 November 2025

Dear Supplier Partners,

Reducing carbon emissions across health systems requires partnership across the value chain. As Chief Procurement Officers (CPOs) from members of the SMI Health Systems Task Force, we ask for your support. We have a shared responsibility and opportunity to contribute to a healthier, more sustainable future by reducing emissions in line with the goals of the Paris Agreement. The healthcare sector contributes around 5% of global greenhouse gas emissions, of which [more than 50% stem from the supply chain](#), and we know that these emissions harm human health. As valued suppliers, you play an essential role in addressing these emissions and your environmental footprint to contribute to a more sustainable and resilient value chain.

In light of this, we have updated the joint, minimum sustainability targets for suppliers which our CEOs first issued in 2023. We ask that you align your operations with these revised targets and engage your own suppliers to do the same:

Updated joint, minimum Supplier Sustainability Targets

- Emissions**
 - Assess and disclose scope 1, 2, and 3 emissions¹; disclose product carbon footprints or life cycle assessments (LCAs) for your top 10 products² (ordered by annual GHG emissions impact) by 2028.
 - Publicly set third-party validated science-based targets³ (near-term and long-term) across Scopes 1, 2, and 3 by 2027.
- Electricity**
 - Source at least 80% renewable electricity by 2030⁴ and publish annual interim progress.
- Heat**
 - Reduce process heat emissions by at least 20% by 2030⁵.
- Resource Efficiency**

Set targets, a credible supporting plan, and demonstrated action in the following areas⁶:

 - Source lower carbon and circular input materials, including sustainable feedstocks for solvents and plastics.
 - Minimise resources by reducing material use; manage unavoidable waste by increasing recycling rates.
 - Reduce emissions from solvent use (e.g. via solvent reuse, solvent recycling).
- Nature & Water**
 - By 2028, assess dependencies, impacts, risks, and opportunities related to pressures on nature⁷ across the value chain and take visible actions in response to the assessment by 2030, including on sustainable and deforestation-free sourcing of key naturally derived commodities.
 - By 2030, set targets and demonstrate action on water. For high water stress or risk areas, set absolute water reduction targets and adopt water stewardship practices⁸. For all areas, measure pollutant release and improve water efficiency.
- Suppliers**
 - Integrate the targets above into contracting for your suppliers.

Sustainable Markets Initiative



To support you and your teams in taking meaningful action on the targets outlined above, we have launched several initiatives as follows:

- Renewable Power and Heat Procurement Programmes.** We have launched joint procurement programmes for renewable electricity in [China](#) and [India](#)⁹ which can be joined. We have also identified clean heat solutions to reduce emissions.
- Sustainable Plastics Sourcing.** We have committed to prioritise low-emission plastics. If you are a plastics supplier, partner with us as we work to substitute fossil-based plastics with lower emissions alternatives within our portfolios, such as certified bio-based plastics. We ask that you provide low-impact options for polyolefins¹⁰ and other plastic materials wherever possible to support our Scope 3 decarbonisation targets.
- Emissions Measurement Tools:**
 - We will be launching a life cycle assessment (LCA) standard later this year. We encourage you to assess your product level impact using this standard and will share relevant trainings to support you here
 - If you are a clinical trials supplier, we encourage you to use our [clinical trial carbon calculator](#) to measure emissions from clinical trials and use the insights to enhance your decarbonisation strategies.
- Dedicated Support Webinars.** Join our webinar series to gain actionable insights on decarbonisation strategies. Register [here](#) to receive updates and invites for upcoming webinars.

As a group of Chief Procurement Officers of pharmaceutical and healthcare companies, we have seen encouraging progress among our top suppliers over the past three years. For example, we have seen the number of suppliers adhering to the [original supplier targets](#) [we set double](#)¹¹, and many suppliers have joined the renewable power procurement programmes we have established.

Sustaining momentum remains a top priority which is why our Chief Procurement Officer Forum meets quarterly to review progress and next steps to decarbonise the value chain.

We are excited to continue collaborating on this journey with you. By working together, within the bounds of competition law, we can advance to net zero health systems and build a healthier, more sustainable future.

Sincerely,

 Natalia Vidmar, AstraZeneca	 Lisa Martin, GSK	 Christoph Buerki, Novartis	 Erich Battanta, Novartis
 Anja Jorgensen, Novo Nordisk	 Marielle Beyer, Roche	 Insub Song, Samsung Biologics	 Jean-Yves Rotté-Geoffroy, Sanofi
 Katiana Iavarone, UCB			

¹ Using methods aligned with the Greenhouse Gas Protocol
² For more information on how to calculate product carbon footprints, please refer to our guidance on product carbon footprints (LCAs) for pharmaceuticals and medical devices, available at [www.astrazeneca.com](#) and [www.novartis.com](#)
³ For more information on how to set science-based targets, please refer to our guidance on science-based targets (SBTs) for pharmaceuticals and medical devices, available at [www.astrazeneca.com](#) and [www.novartis.com](#)
⁴ For more information on how to set renewable energy targets, please refer to our guidance on renewable energy targets (RETs) for pharmaceuticals and medical devices, available at [www.astrazeneca.com](#) and [www.novartis.com](#)
⁵ For more information on how to set heat reduction targets, please refer to our guidance on heat reduction targets (HRTs) for pharmaceuticals and medical devices, available at [www.astrazeneca.com](#) and [www.novartis.com](#)
⁶ For more information on how to set resource efficiency targets, please refer to our guidance on resource efficiency targets (RETs) for pharmaceuticals and medical devices, available at [www.astrazeneca.com](#) and [www.novartis.com](#)
⁷ For more information on how to set nature-related targets, please refer to our guidance on nature-related targets (NRTs) for pharmaceuticals and medical devices, available at [www.astrazeneca.com](#) and [www.novartis.com](#)
⁸ For more information on how to set water stewardship targets, please refer to our guidance on water stewardship targets (WSTs) for pharmaceuticals and medical devices, available at [www.astrazeneca.com](#) and [www.novartis.com](#)
⁹ For more information on how to set renewable energy targets, please refer to our guidance on renewable energy targets (RETs) for pharmaceuticals and medical devices, available at [www.astrazeneca.com](#) and [www.novartis.com](#)
¹⁰ For more information on how to set polyolefin targets, please refer to our guidance on polyolefin targets (POLs) for pharmaceuticals and medical devices, available at [www.astrazeneca.com](#) and [www.novartis.com](#)
¹¹ For more information on how to set supplier targets, please refer to our guidance on supplier targets (STs) for pharmaceuticals and medical devices, available at [www.astrazeneca.com](#) and [www.novartis.com](#)

The Sustainable Markets Initiative (SMI) Health Systems Task Force recent [Open Letter to Supplier Partners](#) shows broad alignment of the Pharmaceutical sector on supplier sustainability (emissions, renewable energy, resource efficiency, nature and water, and cascading standards).

While some AstraZeneca requirements go further, they are directionally consistent with peers. Meeting our standards will streamline your compliance, reduce duplication, and help you satisfy similar expectations from other pharmaceutical clients—enhancing your competitiveness across the sector



Pathway to Net Zero: AstraZeneca program alignment

1. Engage

- Involve leadership
- Gather input from employees/key customers and suppliers
- Form internal working groups and identify 'champions' to ensure buy-in

2. Commit

- Publicly commit then set SBTi target
- Integrate target into business strategy
- Communicate internally

3. Measure

- Conduct an assessment of GHG emissions
- Undergo third party validation of numbers

4. Reduce

- Create a carbon reduction plan
- Implement decarbonisation initiatives
- Create dashboards to track KPI's

5. Communicate

- Share progress via public disclosures
- Create an annual climate impact or ESG statement


6. Mitigate

- Offset any residual, unavoidable emissions using credible, high-quality carbon credits



TBD by supplier



A landscape photograph of a pine plantation. The foreground is filled with young pine trees, their needles and branches visible. In the middle ground, a line of trees separates the foreground from a house with a gabled roof, situated on a slight rise. The background shows rolling hills covered in more trees, fading into a hazy distance. The entire image is overlaid with a semi-transparent purple filter, which softens the colors and adds a monochromatic aesthetic. The text is centered in the middle of the image.

Section 2: Step-by-step for Minimum Requirements

Enabling Small Businesses


- While meeting sustainability expectations can feel challenging for small businesses, there are practical, right-sized pathways to help you succeed and thrive
 - There are streamlined or simplified options available to qualifying SMEs in most areas
 - If you are a small business, please use these to your advantage
 - If you are a large organisation, please ensure the SMEs in your supply chains are aware of the options open to them
- **SME Climate Hub:** This organisation offers [resources and educational materials](#) designed specifically to support SMEs on their net zero journey
 - **SBTi:** The [SME streamlined route](#) enables a simple selection of a target against scopes 1 and 2 only, or the setting of a maintenance target, with a heavily reduced fee
 - **EcoVadis:** The '[small](#)' and, even, '[extra small](#)' organisation types exist with much lower fees and much smaller questionnaires

AstraZeneca's Sustainability Accelerator for Small Businesses: Four-month intensive program to enable small businesses to build sustainability foundations, assess their impacts, navigate through AstraZeneca sustainability requirements and develop roadmap and action plan aligned to expectations



The **Science Based Targets initiative (SBTi)** is a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis.

They develop standards, tools and guidance which allow companies to set greenhouse gas (GHG) emissions reductions targets in line with what is needed to keep global heating below catastrophic levels and reach net-zero by 2050 at latest.



SCIENCE
BASED
TARGETS

DRIVING AMBITIOUS CORPORATE CLIMATE ACTION



SBTi process

For more relating to AstraZeneca's SBTi requirement, review our FAQ'S [here](#).

1. Register

All companies are required to first register with SBTi Services via the Validation Portal.

Create an individual account [here](#) then follow the instructions to create a company account.

More information on the registration process including the information required can be found [here](#).

2. Commit

A formal commitment to setting a SBT should be made within the Validation Portal, via a simple agreement completed by an authorised company executive.²

Your target will then be publicly visible on the SBTi [Target Dashboard](#).

3. Develop

Once committed, you can begin the process of creating targets in line with the SBTi Standard. There are two options:

- [Near-term target](#)
- [Net-Zero target](#)

AstraZeneca requires supplier to set a near-term target at minimum.

SME's have their own streamlined target setting [pathway](#).

4. Submit

Download the [Target Submission Form](#) and complete before submitting along with any supporting documents via the Validation Portal.

Following technical screening, the target validation is completed by SBTi. Ensure you respond to any email communications for more information and make the fee payment.

More detail on costs can be found [here](#).

5. Communicate

One month after your target has been approved it will be published on the '[Companies Taking Action](#)' page on the SBTi website and partner websites.

You will receive a welcome pack with advice on how to communicate your new target to your stakeholders.

6. Disclose

Following approval, you should disclose your companies' emissions annually and monitor your progress towards your target.

SBTi Resource Library accessible [here](#).

² This step is not required for SMEs following the streamlined SME target-setting route



EcoVadis is an Environmental and Social Governance (ESG) assessment company. Since its founding in 2007, EcoVadis has grown to become the world's largest and most trusted provider of business sustainability ratings, creating a global network of more than 100,000+ rated companies. The assessment is customised based on industry, country, and company size.

The Sustainability Scorecard illustrates performance across 21 indicators grouped into 4 main themes:

- Environment (including a Carbon Scorecard)
- Labour & Human Rights
- Ethics
- Sustainable Procurement

The EcoVadis logo is displayed in a dark grey, lowercase sans-serif font. The letter 'v' is stylized with a small green leaf-like shape above its right side. The background of the logo area is a photograph of a family (a man, a woman, and a child) silhouetted against a bright sunset or sunrise in a field. The man is carrying the child on his shoulders, and the woman is standing to the right with her arm raised, looking towards the sun.

EcoVadis process

For more relating to AstraZeneca's EcoVadis requirement, review our FAQ'S [here](#).

1. Registration

Click [here](#) or follow the link in your email invite from AstraZeneca to register on the EcoVadis platform* and provide general information about your company. This data will then be verified by EcoVadis' data management team to customise your questionnaire and subscription offer. More details on subscriptions including pricing can be found [here](#).

*Registering via this link will add your scorecard to the [Responsible Health Initiative \(RHI\)](#) pool. This approach allows trading partners to share one valid assessment with multiple RHI Pharma members, significantly reducing survey fatigue. If you do not wish to share your scorecard with the RHI pool, please reach out and request an alternate invitation link

** See further slides for more information on EcoVadis' carbon section.

2. Questionnaire

After receiving and processing your registration, you will receive a notification with your username and a link to create your password to access the platform, where you can choose your subscription plan and start completing your company's sustainability questionnaire and provide supporting documentation. The questionnaire must be completed within 30 business days. Ensure to complete all sections and provide all metrics including carbon related data, especially where not invited to CDP**

3. Expert analysis

After you submit the questionnaire, EcoVadis' sustainability analysts will collect sustainability-related news about your company from publicly available sources and assess your answers and supporting documents. You can check the estimated publication dates of your results on your EcoVadis Ratings platform but can generally expect a result in 6-8 weeks.

4. Results

Once Expert Analysis is completed by EcoVadis, you will receive an email notification with a link to your scorecard. This scorecard will also be visible to AstraZeneca. You can share that with any other requesting organisations and you must share with AstraZeneca if you did not begin the process with an invite from us. The EcoVadis platform will generate corrective actions based on improvement areas identified in your assessment.

5. Re-assessment

Your scorecard is valid for 12 months and should be updated annually, this will demonstrate any progress from incorporating corrective actions throughout the year. You should begin your re-assessment at least 3 months in advance of scorecard expiry to ensure you experience no period of scorecard expiry.

EcoVadis Help Center accessible [here](#).



EcoVadis scoring categories

For more relating to AstraZeneca's EcoVadis requirement, review our FAQ'S [here](#).



EcoVadis Carbon Scorecard

The standard EcoVadis assessment contains a carbon management questionnaire* and will result in being assigned a carbon management level. AstraZeneca would like to see suppliers' journey to reach at least an **Advanced** level, although meeting our SBTi requirement means you are already well placed to achieve a **Leader** level. Ensure to fully complete the carbon metrics section of your EcoVadis assessment including provision of related metrics, such as energy, waste and water.



Questionnaire Requirements

- 11 questions for large companies, incl. 8 multiple-choice
- 7 questions for SMEs, incl. 4 multiple-choice

Performance level	Insufficient	Beginner	Intermediate	Advanced	Leader
Prerequisite	-	-	-	<ul style="list-style-type: none"> • Public Reporting or CDP Report • 3rd party verification 	<ul style="list-style-type: none"> • Scope 1 + 2 Targets • SBTi target or commitment • Public reporting / CDP Report • 3rd party verification
Results	Company with minimal or no GHG management system	Company with some elements of a GHG management system and/or reporting practice	Company with core elements of a GHG management system	Company with comprehensive GHG management system, public reporting & 3rd party verification	Company with best in class GHG management system and formal GHG emissions reduction target.
Opportunities	Focus on improvement areas to set up foundation for a GHG management system	Focus on setting the core elements of a GHG management system. Including targets for scope 1, 2 emissions & public reporting	Focus on setting target & consider 3rd party verification of disclosed data	Focus on target setting practices. If you haven't done so, consider setting targets across all scopes or align your targets with science based target requirements	Engage and collaborate with a trading partner

* not applicable to extra small organisations (<25 employees)



CDP is a not-for-profit which runs a global environmental disclosure system for investors, businesses, cities, states, and regions. CDP was set-up with the purpose of developing a standardised environmental reporting model which simulates financial accounts.

Invited suppliers are annually required to complete CDP's climate change questionnaire which enables the identification of environmental risk management and mitigation opportunities



CDP process

For more relating to AstraZeneca's CDP requirement, review our FAQ'S [here](#).

1. Activate

Invited suppliers will receive an invite to register on CDP from AstraZeneca around the start of June each year. You must register or log-in to a pre-existing CDP account to activate your participation. You will then receive an invitation to participate in the submission process from CDP and will be able to view the questionnaire. Suppliers requested to disclose to CDP by AstraZeneca will not be required to pay any fees.

The questionnaire is extensive, so you are recommended to begin working on the questionnaire as soon as you receive the invite from AstraZeneca. The key data we require from supplier includes emissions and the verification of those emissions as well as energy related activity.

2. Report

All companies are expected to provide:

- Scope 1 and Scope 2 emissions data
- Scope 3 emissions, categories 1-8 (upstream). All categories need to be provided OR marked as not relevant

Verification of data by an external third party is encouraged.

SME's are able to complete a tailored questionnaire which has fewer questions.

You must complete and submit your data around September or October each year. The specific deadline will be clearly communicated to you by CDP.

3. Results

Your submission will be assessed by CDP and you will receive a CDP score which will represent a combination of your environmental performance and the completeness of your questionnaire submission.

AstraZeneca and any other requesting parties will also receive these results and assess the quality of your submission internally using this to indicate business maturity in carbon management.

CDP Help Center
accessible [here](#).



66% of AstraZeneca's Scope 3 emissions in 2025 were from Purchased Goods & Services, Capital Goods and upstream Transport & Distribution* - i.e. from our supply chain.

To meet AstraZeneca's ambitious GHG emission reduction targets we need to significantly reduce the GHG emissions of our suppliers.

It is critical our suppliers understand our targets and are aligned to our vision to ensure their emissions are as low as possible.


Every supplier should therefore have a Decarbonisation Plan aimed at reducing AstraZeneca allocated emissions by 50% from baseline year of 2024 through the end of 2030.

Decarbonisation Plans for AstraZeneca Allocated Emissions



Decarbonisation Plans for AstraZeneca Allocated Emissions - Process

For more relating to AstraZeneca's GHG methodology [here](#).



• PCF calculation must be aligned with [PACT methodology](#). PACT explicitly requires PCFs to be calculated in accordance with major international standards, including ISO 14040/14044/14067 standards and GHG Protocol Product.
 • PCF for chemicals use [TfS standard](#). PCF for pharma product apply [PAS 2090 standard](#).



Inclusion and diversity (I&D) is fundamental to the success of AstraZeneca because we believe that innovation requires breakthrough ideas that come from a diverse workforce and partners empowered to challenge conventional thinking. Supplier Diversity ensures small and/or diverse-owned businesses have equal access to business opportunities.

We work with suppliers who share our values and show commitment to Human Rights and I&D through robust policies, due diligence, and measurable actions in their workplace and supply chain.



Labour and Human Rights; Inclusion and Diversity (I&D)

Human & Labour Rights

I&D

Our Code of Conduct for Third Parties outlines our requirements for suppliers on Human & Labour Rights:

- **Policy & standards:** human-rights policy aligned to International standards; zero discrimination; safe work; fair pay/hours; freedom of association.
- **No modern slavery/child labor:** Ban forced, bonded, trafficked and child labor; no recruitment fees.
- **Due diligence:** Identify, prevent, mitigate and remediate risks across operations and supply chains; cascade requirements.
- **Worker voice:** Confidential grievance channels; non-retaliation.
- **Governance & training:** Senior accountability; role-based training.
- **Transparency:** Notify AstraZeneca of any actual or suspected cases of modern slavery; provide information on request.

Steps to meet requirements:

1. Establish policies and governance, work towards mapping supply chains, and conduct risk-based human rights assessments.
2. Integrate contract clauses and audit rights, monitor performance, and mitigate potential negative human rights impact in your supply chains.
3. Provide accessible grievance mechanisms, escalate concerns to AstraZeneca, and continuously improve.

1. As part of AstraZeneca's Sustainability Expectations, you will be asked to share your organization's I&D policies and practices with AstraZeneca through the EcoVadis platform. For more guidance on developing such policies, visit EcoVadis Resources.

2. We expect you to commit to a supplier inclusion program and provide equal procurement opportunities to small subcontractors in your supply chain where such opportunities exist. If requested by AstraZeneca, we expect you to provide AstraZeneca's tier 2 spend with small businesses. Please refer to the clauses in your contract.



We depend on materials of natural origin across our value chain, from discovery to the delivery of our medicines to patients. Sourcing materials from nature potentially risks adversely impacting people and the environment.

Well functioning ecosystem services – such as pollination, water purification, climate regulation, and soil health - are crucial to ensure a healthy planet for patients, and business resilience through continuous supply.

When sourcing from nature we must do so sustainably and reduce our impact.



What to expect on Sustainable Sourcing through to 2030


Setting the foundations in 2025

1. Established our key raw material Sustainable Sourcing approach and plans.
2. Readied the business and connected with Suppliers in-scope of EUDR.
3. Built Pharma peer-aligned Sustainable Sourcing Strategies for Lactose and Palm Oil through PSCI.
4. Created internal guidelines to ensure the Sustainable Sourcing of all Biomaterials used for switching sources of fuel, plastics and solvents.

Implementing through to 2030

1. Communicating contract requirements for supply chain certifications of key raw materials such as Timber used for Secondary & Tertiary packaging, Cellulose, Lactose, Aluminium, Talc, Castor Oil, Palm Oil, Carnauba Wax and Sugar.
2. Encouraging key raw material suppliers to develop supply chain social and environmental due diligence systems to assure AstraZeneca of sustainable sources (incl. risk identification, monitoring, remediation, continuous improvement).
3. Aligning requirements for key natural raw materials with Pharma peers.
4. All biomaterial sourcing and switching will adhere to new AstraZeneca guidelines.



The background image shows a scenic view of rolling hills covered in dense pine forests. The hills recede into the distance, creating a sense of depth. A semi-transparent purple overlay is applied across the entire image, which serves as a backdrop for the white text. The text is centered and reads: Section 3: Beyond Minimum Requirements: Sustainability Leadership.

Section 3: Beyond
Minimum Requirements:
Sustainability Leadership



Human Rights

Context

We build trust by demonstrating ethical business practices and fair treatment of people across our value chain. Human rights risks can occur in any supply chain tier, often linked to recruitment practices, vulnerable worker groups, or operations in higher-risk countries and industry sectors.

We expect our suppliers to adhere to the human rights principles and guidance set out in AstraZeneca's [Code of Conduct for Third Parties](#) and to respect internationally recognised human and labour rights, providing safe, fair and inclusive working conditions.

Among the key human rights risks we want to prevent are:

- Modern slavery including forced labour, bonded labour and human trafficking
- Child labour
- Discrimination, harassment and violence
- Unsafe or unhealthy working conditions
- Unfair pay, excessive working hours, and restrictions on freedom of association

AstraZeneca Approach

AstraZeneca takes a structured, multi-layered approach to addressing human rights across our supply chain, enabled by collective actions across three areas: enhancing our policies and standards, identifying risks and priorities, and measuring performance and scaling impact.

Policies & Standards: our Human Rights Standard aligns to the principles of the [UNGPs](#), [ILO](#) and [OECD Guidelines](#), supports compliance with human rights legislation Modern Slavery legislation and EU CSRD, and is reinforced through our Code of Conduct for Third Parties, due diligence processes, contract clauses, and RfX processes.

Identifying Risks & Taking Action: We use our Third-Party Risk Management (3PRM) system to understand our suppliers' human rights risks and flags, with particular focus on high-risk countries and sectors. Also, on an ongoing basis we assess our suppliers' human rights performance through EcoVadis - Labour & Human Rights accounts for 25% of the total score. Suppliers scoring below 45 are prioritised for corrective action.

Measuring Performance & Scaling Impact Our 2026 focus targets: Supplier Engagement & Corrective Actions; Capability Uplift through training for suppliers and procurement teams; and Special Projects for high-risk categories. Progress is reported in our annual Sustainability Impact Report and Modern Slavery Statement

Supplier Best Practice

Suppliers should have a practical, risk-based due diligence process to identify, prevent, mitigate and respond to risks of negative human rights impacts across their operations and supply chain, measured by EcoVadis Labor & Human Rights Subscore (45+). Minimum best practice we recommend suppliers demonstrate:

- Respect human and labour rights
- No modern slavery - no forced labour, bonded labour, or human trafficking
- No child labour
- Fair, inclusive and respectful workplace - no discrimination, bullying, or harassment
- Inclusive supply chains
- Fair pay, lawful working hours, and safe working conditions
- Worker voice and speak-up - freedom of association where lawful, grievance channels, and no retaliation

Further Resources

AstraZeneca

- [AstraZeneca Code of Conduct for Third Parties](#) (Supplier Code of Conduct)
- [AstraZeneca Human Rights Statement](#)
- [AstraZeneca Modern Slavery Statement](#)

External frameworks and guidance

- [UN Guiding Principles on Business and Human Rights \(UNGPs\)](#):
- [International Labour Organization \(ILO\) core labour standards](#)
- OECD Guidelines
- [Ethical Trading Initiative \(ETI\) Base Code](#)
- [EcoVadis Resources on Labour and Human Rights](#)
- [PSCI Principles](#)





Renewable Electricity and Clean Heat

Context

Renewable electricity and clean heat sit at the core of decarbonisation strategies — particularly for energy-intensive sectors such as pharmaceutical manufacturing. Energy use typically represents the largest share of Scope 1 and Scope 2 emissions in GHG inventories.

- Electricity consumption → Scope 2 emissions
- On-site fuel combustion for heating/steam → Scope 1 emissions

Decarbonising these two categories is often the fastest and most controllable lever companies have to reduce operational emissions.

Renewable electricity and clean heat are not standalone sustainability initiatives — they sit within a broader energy efficiency and optimisation strategy.

AstraZeneca Approach

AstraZeneca combines **renewable electricity procurement, on-site generation, energy efficiency improvements, and biomethane fuel switching** to decarbonise both power and heat across its global operations to achieve **100 % renewable energy (including power and heat)**

Large AstraZeneca sites have been upgraded with **efficiency-focused capital projects**, including refits to combined heat and power (CHP) systems and building upgrades, to reduce emissions by lowering heat and power demand.

Electricity & Energy Transition

- AstraZeneca achieved 100% renewable electricity across global operations, utilising a mix of on-site solar installations across multiple countries, long-term Power Purchase Agreements (PPAs) (e.g., a 10-year contract for wind power in Sweden), and renewable certificates (RECs).

Clean Heat & Biomethane Adoption

- Key element of decarbonising heat sits on heat electrification by preparing infrastructure for electric heaters, heat pumps and other electric systems.
- As part of clean heat conversion, AstraZeneca is **shifting from fossil gas to renewable gas (biomethane)** across key sites.
- In the UK, a **15-year partnership with Future Biogas has brought online the country's first unsubsidised biomethane plant** to supply clean heat to our R&D and manufacturing operations — producing about **100 GWh of biomethane annually** (≈20 % of the company's global gas consumption) and displacing significant CO₂ emissions.
- In China, AstraZeneca sources **biomethane-based steam** for our Wuxi site from a municipal-waste-to-biomethane project, reducing Scope 1 and 2 emissions.
- In the U.S., a collaboration with Vanguard Renewables is enabling the supply of **renewable natural gas (biomethane)** to our sites
- AstraZeneca's Rare Disease Unit, **Alexion, is undertaking a 15-year biomethane agreement in Ireland**, transitioning our Irish sites to **100 % renewable biomethane for heat**.

Supplier Best Practice

A typical operational decarbonisation pathway looks like:

1. **Energy efficiency & optimization**
2. **Transition to 100% renewable electricity, through Renewable Energy Certificates (RECs) as part of a Utility contract, and Power Purchase Agreements (PPAs)**
3. **Electrification of heat, for lower temperature demands**
4. **Advanced fuels (biogas, biomass, hydrogen) for residual demand**

In this sequence:

- Renewable electricity is a fast, scalable lever.
- Clean heat is the key for deep Scope 1 reduction.
- Energy efficiency determines the cost and feasibility of both.

This follows the core decarbonisation principle:
Avoid → Reduce → Replace

Further Resources

[AstraZeneca Renewable energy approach](#)

[Energize](#) Pharma program with Schneider Electric providing education and market access to RECs and PPAs

[RE100](#) Accelerate towards zero carbon electricity

[EV100](#) Making electric transport by 2030

[Clean Heat Program](#) with Secaro supporting pharma suppliers on Industrial Heat Decarbonization |

[Renewable Thermal Collaborative \(RTC\)](#)

RTC is the global coalition focused on decarbonizing thermal energy use by scaling up renewable heating and cooling technologies.

[RTC Electrification Action Plan](#) Roadmap for industrial electrification of heat, outlining technology pathways (heat pumps, electric boilers) and market solutions.

[RTC Process Heat Electrification](#) Resources focused on heat electrification solutions and tools

[RTC Heat Pump Decision Support Tools](#)

[RTC Utility Engagement Playbook for Industrial Customers](#)

[Renewable Electricity for Businesses](#) - Climate Partner guide

[IEECP Resources](#) - direct access to project tools, case studies and publications from Institute for European Energy and Climate Policy.





Product and Site Level Carbon Footprints

Context

As companies advance science-based net-zero commitments, carbon management has shifted from high-level corporate totals to more granular measurement at the product and operational site levels.

For a global pharmaceutical company, whose emissions spread across complex global supply chains, this is key to drive meaningful reductions. A product carbon footprint (PCF) quantifies GHG emissions across the full lifecycle of a medicine - from raw material extraction, API production to manufacturing, distribution, use, and end-of-life - helping identify hotspots such as propellants, energy use, or packaging, and enabling eco-design, green chemistry. In parallel, site-level carbon footprints measure Scope 1, 2 emissions and allocated Scope 3 at individual facilities, supports renewable energy transitions, heat electrification, efficiency improvements, and capital prioritization.

Together, these approaches provide the transparency needed to align with frameworks such as the Science Based Targets Initiative (SBTi) and turn net-zero commitments into targeted, actionable reductions.

Supplier Best Practice

Develop a structured, replicable and transparent approach to measure, manage, and reduce GHG emissions at both Site level (manufacturing facility emissions) and Product level.

Site-Level Carbon Footprint

- Annual GHG inventory (Scope 1 & 2; relevant Scope 3).
- Third-party verification.
- Energy source breakdown (electricity, gas, steam).
- Clear emission factors and methodology disclosure.

Product Carbon Footprint

- PCF data shared in standardised format, following PACT methodology.
- Compliant with PAS 2090:2025 standard for pharmaceutical products.
- Compliant with TfS standards for chemical products.

Further Resources

[AstraZeneca Product Sustainability](#)

[PACT Methodology](#) for PCFs from WBCSD. PACT is built as a standardised, interoperable way to exchange PCF data across value chains. PACT explicitly requires PCFs to be calculated in accordance with major international standards, including ISO 14040/14044/14067 standards and GHG Protocol Product.

[PAS 2090:2025](#) Pharmaceutical products standard for life cycle assessments.

[PAS 2090:2025 - Technical Guidance](#)

[PAS 2090:2025 - Supplier FAQ](#)

[PAS 2090:2025 - Infographic](#)

[PAS 2090:2025 - Overarching program abstract](#)

[PSCI's LCA training](#) to upskill your teams

[Together for Sustainability \(TfS\)](#) PCF toolkit for Chemical supply chain. To help you take your first step in your PCF journey, TfS gathered useful resources and training material together in one place.

[Activate Program](#) to help Pharmaceutical Supply Chain to set out Site Level Carbon Footprints and Site Decarbonisation plans

AstraZeneca Approach

AstraZeneca has developed a data-driven approach to measuring and managing carbon footprints as part of its broader Ambition Zero Carbon strategy. AstraZeneca's methodology integrates lifecycle thinking, science-based targets, internal metrics, and external collaboration to reduce climate impacts throughout its value chain.

AstraZeneca conducts Life Cycle Assessments (LCAs) for its medicines according to ISO 14040/14044/14067 standards and GHG Protocol Product Standard to understand environmental impacts — including carbon emissions — across the entire product life cycle (from raw material sourcing through manufacturing, packaging, distribution, use and end-of-life). The mentioned frameworks underpin our methodology and ensure consistency and credibility in our LCA and PCF assessments.

LCAs feed into product sustainability strategies and help prioritize interventions where they can most reduce greenhouse gas emissions.

AstraZeneca applies green chemistry principles and resource-efficiency metrics such as Process Mass Intensity (PMI) in R&D and manufacturing to reduce energy, materials use, and waste - helping lower product-related carbon emissions.

To support the building of our products LCAs we rely on emissions (GHG, water, waste) data from our suppliers at site level from Activate Program and from the PCFs provided directly by our suppliers.





Biomaterials

Context

Biomaterials are those made from natural, organic materials (biosources) as opposed to fossil resource to form bioplastic, biosolvents or biofuels. However, when we source from nature we can unlock GHG reductions but also increase exposure to different risks.

We have established Biomaterial guidelines to ensure carbon savings which motivate switching are real and verifiable, and to ensure risk factors linked to 'nature' and 'people' topics are included in our decision making.

Supplier Best Practice

When a biomaterial is sourced from Post-consumer waste, the associated nature risks are inherently lower, because they carry no (new) environmental burden. Country of origin & nature-related production risks are not applicable.

This is defined as waste generated after consumer use, including bio-based end-of-life products (Used Cooking Oil), consumer food waste, and municipal/urban waste.

Further Resources

Definitions

Post-consumer waste

"Post-consumer material originates from the use of a product"

"Material generated by households or by commercial, industrial and institutional facilities in their role as end-users of the product which can no longer be used for its intended purpose."

Pre-consumer waste/by-product

"Pre-consumer material originates from the production of a product."

"Material diverted during a manufacturing process"

Agricultural and processing waste/by-products are pre-consumer

AstraZeneca Approach

1. **Transparency** – we always need to know the feedstocks used to produce the biomaterials, with quantities and production origin (country level as minimum) disclosed.
2. **Food security** – we prohibit the sourcing of 1st Generation feedstocks (dedicated crops) from Low-Income Food Deficit Countries (LIFDC)
3. **Chain of Custody (CoC)**– we must be able to classify feedstocks accurately. For biomaterials made from raw materials on the High Impact Commodity SBTN list, we will increasingly require Segregated or Identity Preserved Chain of Custody sources.
4. **Certificates** – we require third party certification evidence to ensure materials are sustainably sourced, with a focus on zero deforestation, avoidance of land use change and upholding labour & human rights. Certification requirements vary according to raw material.





Nature

This guidance is intended for suppliers who source nature-based commodities indirectly or have embedded relationships with nature. Direct suppliers of key raw materials have already been engaged in Sustainable Sourcing programs.

Context

All businesses draw from nature, even when not immediately visible. *Ecosystem services*—such as pollination, water purification, climate regulation, and soil health—underpin operations, supply continuity, and cost stability across sectors.

Typical business touchpoints with nature:

- Paper and packaging: fiber sourcing linked to deforestation and land-use change.
- Food and catering: agricultural commodities tied to biodiversity loss, water use, and GHG emissions.
- Water usage: operational and utility water that affects local watershed health and ecosystem resilience.
- Facilities and logistics: energy, land, and materials with pollution, waste, and GHG footprints.
- Pharma-relevant inputs: medicinal plants, agricultural derivatives, and other nature-based raw materials vulnerable to climate change and resource depletion.

Supplier Best Practice

AstraZeneca’s detailed best practice for indirect sourcing is under development; we will share expectations and metrics in future communications.

For now, we recommend suppliers to consider the following:

- Map indirect categories with nature and conduct a nature risk screening across upstream tiers.
- Establish traceability to origin for forest- and agri-linked commodities; align with EUDR and relevant labour due diligence laws.
- Adopt policies covering primary forests, peatlands, and high biodiversity areas, with time-bound implementation and supplier verification.
- Set KPIs, disclose progress, and use recognized frameworks for nature-related risk management.

Further Resources

- [AstraZeneca Sustainable Sourcing framework](#).
- [WBCSD Nature Action Portal](#): Refer to the WBCSD Nature drives and guidance for best practice, implementation tools, and sector case studies on nature-positive strategies.

AstraZeneca Approach

AstraZeneca has developed material specific roadmaps, informed by supplier engagement via Worldfavor, covering traceability, deforestation & land use, water stewardship, pollution & waste, GHG emissions, human rights, animal welfare, and governance. AstraZeneca’s material-dependent definition for indirect sourcing is still being finalized and will be shared with suppliers when available.

To review your current approach, businesses can utilise the [AstraZeneca Sustainable Sourcing framework](#) and our emphasis on:

- Traceability and transparent governance
- EUDR-aligned practices for forest-risk commodities
- Water stewardship and basin-level risk management
- Pollution prevention, waste minimization, and circularity
- GHG reduction across scopes, including land-use impacts
- Human rights and animal welfare safeguards across tiers





Sustainable Procurement

Context

Sustainable Procurement is defined as “A process whereby organizations meet their needs for goods, services, works and utilities in a way that achieves value for money on a whole life basis in terms of generating benefits not only to the organization, but also to society and the economy, whilst minimizing damage to the environment”. (ISO 20400:2017 - Sustainable Procurement)

Supplier Best Practice

1. Have established and can prove implementation of a **supplier code of conduct**.
2. Clear sustainability guidance for strategy creation and evaluation.
3. Communicate to suppliers' clear sustainability RFP requirements and award criteria. (e.g. sustainability weighing scoring)
4. Standardised contract clauses for code of conduct compliance, audit rights, disclosure/reporting, subcontractor flow-down and remediation/termination for serious breaches.
5. Sustainability embedded in Supplier Performance Management (SRM) process
6. Sustainability capability uplift plans for their Procurement teams.

Further Resources

[The Guide](#) developed by the Sustainable Procurement Pledge (SPP) for embedding sustainability in Procurement.

[Ecovadis Sustainable Procurement Barometer 2024](#) underscores shifts in purchasing priorities, tools for tracking sustainability, approaches to engaging suppliers, and the integration of these elements into internal processes.

[ISO 20400 global community of practice around ISO 20400 and sustainable procurement](#)

[Sustainable Procurement \(SP\) | Sustainability Advantage](#)

AstraZeneca Approach

- Our approach to sustainability and the actions we take annually are detailed in the “[Our Sustainability Impact](#)” report.
- We maintain a [Code of Conduct for Third Parties](#) that translates our internal Code of Ethics into content applicable to our supply chain.
- We host a [Supplier Sustainability Hub](#) on our website to provide clear, up-to-date information on our sustainability requirements; insights; support programs; training opportunities via the Supplier Guide and Supplier Sustainability Newsletter; and a contact channel for sustainability queries.
- A mandatory 10% sustainability weighting in our sourcing events.
- Sustainability requirements in contract clauses.
- We use SBTi commitment as a criterion for Preferred Supplier status.
- We have developed internal tools such as LENS PowerBI sustainability dashboard to facilitate supplier sustainability comparisons.
- An *unsustainable supplier* is clearly defined, and a process is in place to manage such suppliers.



The background image shows a scenic view of rolling hills covered in dense pine forests. The hills recede into the distance, creating a sense of depth. A semi-transparent purple color is overlaid on the entire image, which serves as a background for the white text. In the middle ground, a small building with a gabled roof is visible on a hillside. The overall atmosphere is serene and natural.

Section 4: Further Resources and Support

Extra Resources

Broad Supplier Sustainability Resources:

- **Sustainable Healthcare Coalition** | A healthcare sector-led group that looks for the greatest opportunities to inspire sustainable practices in healthcare through collaboration
- **Sustainable Procurement Pledge Beyond The Guide Deepdive** | Pharma & Lifesciences
- **Embedding Project** | Useful resources that help companies embed sustainability across their operations and decision-making
- **PSCI Maturity Models** | Models to self assess your maturity across various sustainability areas

Decarbonisation Resources:

- **Scope 3 Peer Group** | Keep track of rapidly-evolving scope 3 best practice and guidance to make faster and more confident progress, together
- **WBCSD Resources** | The Climate Drive
- **Net-Zero Journey for Companies**
- **Pharma Net- Zero Delivery Playbook** | This PSCI Playbook builds on that work to provide 24 detailed emissions reduction initiatives across 7 impact areas that map to the drug development lifecycle.

SME Resources:

- **SME Climate Hub** | The SME Climate Hub is a non-profit global initiative that empowers small to medium sized companies to take climate action and build resilient businesses for the future



Further support

Visit our FAQs and contact us via AstraZeneca's [Supplier Sustainability Hub](#)

SBTi Resource Library accessible [here](#).

EcoVadis Help Center accessible [here](#).

CDP Help Center accessible [here](#).

